Saffron Walden, UK, 14th June 2021 / Sciad Newswire / Domainex is delighted to announce that it has been awarded ‘Best CRO’ at the OBN Awards 2020. Dr Tom Mander, CEO, Dr Ray Boffey, Executive Director of Medicines Research, and Dr Cat Stace, Director of Business Development, attended the postponed awards ceremony in London on Friday 11th June 2021.
Over the past year, Domainex has made significant investment in new technology to support its clients’ research needs and secured an out-licencing deal with Invivoscribe Inc. of a therapeutic drug candidate to treat patients with multiple myeloma. The company grew its top line by ~45% in 2020 and welcomed over 30 new colleagues to its team to further extend its drug discovery offering, despite the challenges faced as a result of the pandemic. To support this growth, Domainex launched a new brand and website, and has seen exciting changes in leadership including Dr Tom Mander moving from COO to CEO, Dr Eddy Littler returning to the company as Non-Executive Chairman, David Cronk joining as Chief of Staff and Dr Ray Boffey’s promotion to Executive Director of Medicines Research.
This progress, along with the continued hard work and excellence of all team members, has allowed Domainex to expand the high-quality services it offers to its clients and partners on a 7-day/week basis. The ability to create and deliver tailor-made drug discovery programmes has helped to build Domainex’s reputation as a reliable and innovative CRO of the highest standard.
OBN acknowledged Domainex’s achievements and innovations in the life sciences industry as part of a continued effort to meet previously unmet clinical needs. Furthermore, it recognised the strong leadership, excellent customer-care, and collaborative and integrated work ethos. Presenting Domainex with the award, the judges commented: “The winner in this category were the only finalist that named their customers and provided excellent customer testimonials. They have their own product programme licensed out and have a clear approach to their robust and effective strategy.”
Tom Mander, CEO of Domainex, commented, “Customer focus is a core value that we are incredibly proud of at Domainex, and we are delighted that this has been recognised by OBN with this award. I would like to thank our team for their consistent hard work and positive can-do approach while facing the additional challenges created by the pandemic. It is the amazing attitudes of our team that allows Domainex to offer high quality services and remain a leader in the field of drug discovery.”
Congratulations to the other finalists and thank you to OBN for arranging the awards and for its continued commitment to supporting such an important industry.
For more information, contact:
Dr. Tom Mander, CEO
Media Relations – Sciad Communications
Deborah Cockerill / Juliette Craggs / Katie Warren
T: +44 (0)20 3405 7892
Notes to Editors
About Domainex Ltd.
Domainex is a leading integrated medicines research service partner working with ambitious life science organisations from around the globe. We have been setting new standards in research since 2001, working collaboratively with pharmaceutical and biotechnology companies, patient foundations and leading academic institutions.
We provide innovative and customised assay and structural biology combined with computational, synthetic, medicinal and analytical chemistry services to advance the disease research projects of our partners, from target expression to pre-clinical development candidate nomination. Working with Domainex maximises the chance of successful progression for our partners’ research and our approach consistently saves up to 30% of the time needed to discover new medicines by comparison with the industry average. Our innovative science and extensive technical capabilities enable us to produce novel medicines to treat diseases with strong commercial potential. We work closely and collaboratively with our customers to understand their aspirations, bringing our ideas, know-how and wealth of experience to bear on their projects.
Our highly qualified and experienced team of dedicated research scientists has an unrivalled breadth of knowledge, access to a wide range of technologies and a proven track record of successful innovation in solving research challenges including being named on over 60 patent applications and the invention of numerous candidate drugs. We aim to deliver successful outcomes efficiently and quickly, setting the highest possible benchmark in medicines research.
Full information about Domainex and our award-winning services can be found at www.domainex.co.uk.